Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Revance Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Revance Therapeutics Inc market cap is $381.02M.
What is the 52-week high for Revance Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Revance Therapeutics Inc 52 week high is $7.56 as of September 11, 2025.
What is the 52-week low for Revance Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Revance Therapeutics Inc 52 week low is $2.30 as of September 11, 2025.
What is Revance Therapeutics Inc stock price today?
Revance Therapeutics Inc stock price today is $3.65.
What was Revance Therapeutics Inc stock price yesterday?
Revance Therapeutics Inc stock price yesterday was $3.64.
What is the PE ratio of Revance Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Revance Therapeutics Inc’s P/E ratio is -1.90.
What is the Price-to-Book ratio of Revance Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Revance Therapeutics Inc P/B ratio is -2.3485.
What is the 50-day moving average of Revance Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Revance Therapeutics Inc 50-day moving average is $3.41.
